Midodrine: Difference between revisions
Elcatracho (talk | contribs) (→Common) |
Elcatracho (talk | contribs) |
||
| Line 29: | Line 29: | ||
*Supine hypertension | *Supine hypertension | ||
*Acute renal disease, urinary retention | *Acute renal disease, urinary retention | ||
*Pheochromocytoma | *[[Pheochromocytoma]] | ||
*Thyrotoxicosis | *[[Thyrotoxicosis]] | ||
*Caution with: | *Caution with: | ||
**Concomitant beta-blockers or digoxin (reflex bradycardia) | **Concomitant [[beta-blockers]] or [[digoxin]] (reflex bradycardia) | ||
**Concomitant use of drugs that increase BP (e.g. phenylephrine, levothyroxine, pseudoephedrine) | **Concomitant use of drugs that increase BP (e.g. [[phenylephrine]], [[levothyroxine]], [[pseudoephedrine]]) | ||
**Concomitant MAOIs or linezolid | **Concomitant MAOIs or [[linezolid]] | ||
**DM | **DM | ||
**Renal or hepatic impairment | **Renal or hepatic impairment | ||
Latest revision as of 16:08, 12 January 2022
Administration
- Type: Vasopressors, alpha-1 agonist
- Dosage Forms:
- Routes of Administration: PO
- Common Trade Names: ProAmatine, Orvaten
Adult Dosing
- 2.5-10mg PO q8h
Pediatric Dosing
Safety/efficacy not established
Special Populations
Pregnancy Rating
- Category C
Lactation risk
- Unknown if excreted in breastmilk
Renal Dosing
- Adult: 2.5mg PO q8h, increase as tolerated
Hepatic Dosing
- Adult: Use caution
Contraindications
- Allergy to class/drug
- Severe heart disease
- Supine hypertension
- Acute renal disease, urinary retention
- Pheochromocytoma
- Thyrotoxicosis
- Caution with:
- Concomitant beta-blockers or digoxin (reflex bradycardia)
- Concomitant use of drugs that increase BP (e.g. phenylephrine, levothyroxine, pseudoephedrine)
- Concomitant MAOIs or linezolid
- DM
- Renal or hepatic impairment
- Vision problems
Adverse Reactions
Serious
Common
- Paresthesias
- Piloerection, pruritus, rash, erythema multiforme, flushing
- Hypertension
- Urinary retention or urgency
- Abdominal pain, nausea, xerostomia
- Chills
- Anxiety, insomnia, somnolence, weakness
- Confusion, dizziness
- Headache
- Hyperesthesia
Pharmacology
- Half-life: 3-4h
- Metabolism: Enzymatic hydrolysis in systemic circulation
- Excretion: Renal
Mechanism of Action
- Selective alpha-1 adrenergic agonist